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Human cytomegalovirus (HCMV) is a
ubiquitous pathogen linked to a high risk
of morbidity in immunologically sup-
pressed and immunodeficient patients,
and it is one of the leading viral causes
of congenital infections. In addition,
HCMV infections have been implicated
in several chronic diseases.1 So far, strat-
egies for copingwith the consequences of
HCMV infection are limited because of
an incomplete understanding of viral
pathogenesis. After primary infection,
the immune response terminates the rep-
lication of the virus, but the virus persists
in infected hosts for a lifetime and is able
to reactivate despite the presence of sig-
nificant preexisting immunity. The
major obstacle to HCMV research is
the virus’s strict species specificity, which
limits the use of experimental animals in
HCMV research. Thus, research on ani-
mal cytomegaloviruses (CMVs) is essen-
tial for gaining insight into HCMV
pathogenesis and immune surveillance.
Among the animal CMVs, murine
CMV (MCMV) is the most widely used
model because it shares many biological,
genetic and pathological properties with
HCMV.2
In this special issue of Cellular &
Molecular Immunology, several articles
are included that discuss recent develop-
ments in CMV immunobiology, with an
emphasis on the viral manipulation of the
immune response during primary and
latent infections, the pathogenesis of con-
genital infections and novel strategies for
intervention approaches, including CMV
vaccines.
The hallmark of all CMVs is the pres-
ence of a large number of immunoevasion
genes that target the immune response
mechanism of the host.3,4 Although the
number of immunoevasion genes under-
scores their significance to the immuno-
biology of the viral infection, we still do
not understand their overall importance
for the virus–host interaction and whether
they benefit only the virus or whether
some of them are also useful to the hos-
t(for example, in limiting immunopat-
hological reactions). Notably, despite
numerous immunoevasive mechanisms
of CMV during primary infection, this
virus induces potent immune responses
that are able to contain its spread and
establish latency. In contrast with our
understanding of the role of viral immu-
noevasins during lytic infection, little is
known about the role of CMV immune
evasion during latency. Current data show
that HCMV manipulates the immune
response during latency and has pro-
found effects on survival and the preser-
vation of the latent viral genome.5 In this
special issue, Wills et al. have summar-
ized strategies for immune evasion dur-
ing latent HCMV infection and have
discussed how the understanding of
these mechanisms could help in design-
ing new approaches for targeting latent
HCMV.6 The ultimate aim of these
approaches is to prevent reactivation
and life-threatening disease in some
patient groups.
CD81 T cells play an essential role in
the control of CMV infection. Their pro-
tective capacity is associated with the
emergence of epitope-specific effector
memory T cells, which provide long-term
protection and apparently undergo con-
tinuous activation and proliferation.
These virus-specific CD81 T cells have
been shown to slowly accumulate after
primary infection in a process known as
CD8 inflation.7–9 In their review article,
Halenius et al.10 have extensively reviewed
the immune evasion strategies used by
HCMV to manipulate both classical and
non-classical MHC I molecules. By doing
so, this virus manipulates the functions of
CD81 T cells and NK cells. The authors
have also highlighted the questions that
still remain to be addressed, thus provid-
ing a direction for future work. In addi-
tion, Lucin et al.11 have reviewed the
Faculty of Medicine University of Rijeka,
Department of Histology and Embryology and
Center for Proteomics, Rijeka, Croatia
Correspondence: S Jonjic, Faculty of Medicine
University of Rijeka, Department of Histology and
Embryology and Center for Proteomics, Brace
Branchetta 20, 51000 Rijeka, Croatia.
E-mail: stipan.jonjic@medri.uniri.hr
Received: 8 December 2014; Revised: 8
December 2014; Accepted: 8 December 2014
Cellular & Molecular Immunology (2015) 12, 125–127
 2015 CSI and USTC. All rights reserved 1672-7681/15 $32.00
www.nature.com/cmi
endocytic trafficking of immune recog-
nition molecules during CMV infection,
emphasizing the mechanisms by which
this virus affects the endosomal system
and modulates endocytic trafficking.11
CMVs are a continuous source of sur-
prise with respect to the mechanisms
that they use to manipulate host cellular
functions. In this regard, Becker et al.12,13
have presented some original studies, in
which they have expanded upon their
own previously published data, revealing
an as-yet unknown role of mast cells in
the early immune response to MCMV
infection, particularly in the recruitment
of CMV-specific CD81 T cells to the site
of infection.12,13 This group has charac-
terized two waves of mast cell degranula-
tion upon CMV infection, occurring at
early and later times after infection. They
have provided evidence that the first
wave of mast cell degranulation is
dependent on the TLR3/TRIF signaling
pathway and that the second wave is
caused by the infections of these cells,
which occur independent of TLR3/
TRIF signaling.
An in-depth understanding of the
immune responses to various pathogens
is a prerequisite for designing new anti-
viral strategies, including vaccines. It is
worth mentioning that the immune res-
ponse induced by natural infection fre-
quently does not provide sufficient
protection against re-infection and disease
with the same pathogen. Therefore, we
need approaches that are able to induce
a level of protective immunity that is
superior to that induced by natural infec-
tion. CMV belongs to this group of
viruses because, at least in some settings,
such as congenital infection, maternal
pre-existing immunity does not prevent
fetal infection. The review article by
McCormick and Mocarski14 focuses on
HCMV vaccine strategies and immune
mechanisms that determine the success
of a vaccine. Much attention has been
paid to the immune mechanisms govern-
ing the transplacental transmission of
HCMV during pregnancy and the
importance of recurrent infection in the
pathogenesis of congenital HCMV dis-
eases. The authors have emphasized that
not only vaccines for HCMV-seronegative
individuals but also approaches to boost
immunity in CMV-seropositive indivi-
duals are needed. In this respect, studies
of mouse models have contributed a
great deal to our understanding of the
pathogenesis of congenital CMV infec-
tion. Newborn mice are developmentally
similar to late second trimester human
fetuses, and MCMV infection delivered
by intraperitoneal inoculation to these
mice leads to central nervous system
infection, the pathogenesis of which
resembles that in the HCMV-infected
human fetus. Slavuljica et al.15 have
discussed the major findings in the
MCMV model and have summarized
many aspects of congenital HCMV
infection of the central nervous system,
including developmental abnormalities,
inflammatory lesions and functional
alterations.
In summary, the significance of CMV
research lies both in the advancement of
our basic knowledge of viral infection and
in the possibility of designing new and
more efficient anti-viral treatments,
including CMV vaccines. There is still a
need for a deeper understanding of the
immunological determinants that predis-
pose individuals to infection because the
clinical expression of HCMV infection is
clearly correlated with the immune res-
ponse of the host. To design more
efficient prophylactic and therapeutic vac-
cines, it is necessary to manipulate the
viral immunoevasion of the innate and
adaptive immune responses to fine-tune
them so that more efficient antiviral anti-
bodies and/or more efficient T-cell res-
ponses will be generated, as has recently
been shown for MCMV expressing the
cellular ligand for NKG2D receptor.16
Special attention should be paid to the
mechanisms of congenital HCMV infec-
tion. More efficient immune intervention
approaches (such as vaccines) are needed
to control the virus at the maternal–fetal
interface because it is now clear that pre-
existing maternal immunity is insufficient
for preventing infection and disease in the
fetus. In summary, it can be concluded
that experimental animal models will
continue to be an essential source of
information about CMV pathogenesis in
the future.
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